TY - JOUR
T1 - Clinicopathological Significance and Prognostic Role of High Mobility Group Box 1 (HMGB1), Toll-Like Receptor (TLR) 2 and TLR4 in Breast Cancer
AU - Taguchi, Reina
AU - Yamaguchi-Tanaka, Mio
AU - Takagi, Kiyoshi
AU - Sato, Ai
AU - Miki, Yasuhiro
AU - Miyashita, Minoru
AU - Suzuki, Takashi
N1 - Publisher Copyright:
© 2024 The Japan Society of Histochemistry and Cytochemistry.
PY - 2024
Y1 - 2024
N2 - High-mobility group box 1 (HMGB1) functions as damage-associated molecular pattern (DAMPs), released into extracellular space during cellular stress. Extracellular HMGB1 act as signal molecules through Toll-like receptor (TLR) 2 or TLR4, exerting diverse functions in both normal cells and malignant cells including breast cancer. However, their comprehensive examination in breast cancer tissues is lacking. Thus, we immunolocalized them in 112 breast cancer tissues, correlating their immunoreactivity with clinicopathological parameters and clinical outcomes to clarify their significance in breast cancer. We demonstrated that nuclear HMGB1 immunoreactivity was correlated with tumor progression and longer disease-free survival. In contrast, TLR2 immunoreactivity was correlated with increased cell proliferation and shorter disease-free survival, dependent on cytoplasmic HMGB1 immunoreactivity. Additionally, TLR4 immunoreactivity correlated with chemoresistance, regardless of cytoplasmic HMGB1 immunoreactivity. It was therefore considered that TLR2 collaboratively contributed to breast cancer progression with HMGB1-DAMPs to become a worse prognostic factor. Meanwhile, TLR4 served as a worse prognostic factor associated with chemoresistance, irrespective of HMGB1.
AB - High-mobility group box 1 (HMGB1) functions as damage-associated molecular pattern (DAMPs), released into extracellular space during cellular stress. Extracellular HMGB1 act as signal molecules through Toll-like receptor (TLR) 2 or TLR4, exerting diverse functions in both normal cells and malignant cells including breast cancer. However, their comprehensive examination in breast cancer tissues is lacking. Thus, we immunolocalized them in 112 breast cancer tissues, correlating their immunoreactivity with clinicopathological parameters and clinical outcomes to clarify their significance in breast cancer. We demonstrated that nuclear HMGB1 immunoreactivity was correlated with tumor progression and longer disease-free survival. In contrast, TLR2 immunoreactivity was correlated with increased cell proliferation and shorter disease-free survival, dependent on cytoplasmic HMGB1 immunoreactivity. Additionally, TLR4 immunoreactivity correlated with chemoresistance, regardless of cytoplasmic HMGB1 immunoreactivity. It was therefore considered that TLR2 collaboratively contributed to breast cancer progression with HMGB1-DAMPs to become a worse prognostic factor. Meanwhile, TLR4 served as a worse prognostic factor associated with chemoresistance, irrespective of HMGB1.
KW - HMGB1
KW - Toll-like receptor
KW - breast cancer
KW - immunohistochemistry
KW - prognostic factor
UR - http://www.scopus.com/inward/record.url?scp=85192503759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85192503759&partnerID=8YFLogxK
U2 - 10.1267/ahc.24-00006
DO - 10.1267/ahc.24-00006
M3 - Article
AN - SCOPUS:85192503759
SN - 0044-5991
VL - 57
SP - 75
EP - 83
JO - Acta Histochemica et Cytochemica
JF - Acta Histochemica et Cytochemica
IS - 2
ER -